These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 31434965

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Galectin‑3 blockade suppresses the growth of cetuximab‑resistant human oral squamous cell carcinoma.
    Yin P, Cui S, Liao X, Yao X.
    Mol Med Rep; 2021 Oct; 24(4):. PubMed ID: 34328195
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
    Yoshizawa K, Nozaki S, Kitahara H, Kato K, Noguchi N, Kawashiri S, Yamamoto E.
    Oncol Rep; 2011 Dec; 26(6):1555-60. PubMed ID: 21833477
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Urinary-type plasminogen activator receptor (uPAR) modulates oral cancer cell behavior with alteration in p130cas.
    Shi Z, Liu Y, Johnson JJ, Stack MS.
    Mol Cell Biochem; 2011 Nov; 357(1-2):151-61. PubMed ID: 21630091
    [Abstract] [Full Text] [Related]

  • 8. Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma.
    Park SJ, Kim MJ, Kim YK, Kim SM, Park JY, Myoung H.
    Cancer Lett; 2010 Jun 01; 292(1):54-63. PubMed ID: 19959278
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Resistance of oral squamous cell carcinoma cells to cetuximab is associated with EGFR insensitivity and enhanced stem cell-like potency.
    Ohnishi Y, Minamino Y, Kakudo K, Nozaki M.
    Oncol Rep; 2014 Aug 01; 32(2):780-6. PubMed ID: 24926885
    [Abstract] [Full Text] [Related]

  • 12. Simultaneous β1 integrin-EGFR targeting and radiosensitization of human head and neck cancer.
    Eke I, Zscheppang K, Dickreuter E, Hickmann L, Mazzeo E, Unger K, Krause M, Cordes N.
    J Natl Cancer Inst; 2015 Feb 01; 107(2):. PubMed ID: 25663685
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Anti-EGFR antibody cetuximab is secreted by oral squamous cell carcinoma and alters EGF-driven mesenchymal transition.
    Fujiwara T, Eguchi T, Sogawa C, Ono K, Murakami J, Ibaragi S, Asaumi JI, Okamoto K, Calderwood SK, Kozaki KI.
    Biochem Biophys Res Commun; 2018 Sep 10; 503(3):1267-1272. PubMed ID: 30017201
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Cetuximab-resistant oral squamous cell carcinoma cells become sensitive in anchorage-independent culture conditions through the activation of the EGFR/AKT pathway.
    Ohnishi Y, Yasui H, Kakudo K, Nozaki M.
    Int J Oncol; 2015 Dec 10; 47(6):2165-72. PubMed ID: 26497980
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. uPAR-expressing melanoma exosomes promote angiogenesis by VE-Cadherin, EGFR and uPAR overexpression and rise of ERK1,2 signaling in endothelial cells.
    Biagioni A, Laurenzana A, Menicacci B, Peppicelli S, Andreucci E, Bianchini F, Guasti D, Paoli P, Serratì S, Mocali A, Calorini L, Del Rosso M, Fibbi G, Chillà A, Margheri F.
    Cell Mol Life Sci; 2021 Mar 10; 78(6):3057-3072. PubMed ID: 33237352
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.